Hemophilia Market Report 2026

The hemophilia market size has grown strongly in recent years. It will grow from $14.98 billion in 2025 to $16.21 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to improved availability of clotting factor concentrates, expansion of prophylactic treatment adoption, growth in hemophilia awareness programs, advancements in recombinant factor production, increased access to specialized care centers.

The hemophilia market size is expected to see strong growth in the next few years. It will grow to $23.17 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing approvals of gene therapies, rising adoption of personalized treatment approaches, expansion of home infusion programs, growing investments in rare disease research, increasing focus on quality-of-life improvement. Major trends in the forecast period include increasing adoption of long-acting clotting factor therapies, rising focus on gene therapy for hemophilia, growing use of home-based treatment regimens, expansion of personalized prophylactic treatment plans, enhanced integration of digital patient monitoring.

The rising incidence of genetic abnormalities is expected to drive the growth of the hemophilia market in the coming years. Genetic abnormalities, also known as genetic mutations or disorders, involve changes in an individual’s DNA sequence that can result in various health conditions and physical traits. Hemophilia treatments aim to prevent or control bleeding episodes, minimize complications, and improve the quality of life for affected individuals. For example, in October 2024, the Cystic Fibrosis Trust, a UK-based charity supporting people with cystic fibrosis, reported that registered patients increased from approximately 11,148 in 2022 to 11,318 in 2023, reflecting a 1.5% year-over-year rise. Consequently, the growing occurrence of genetic abnormalities is fueling hemophilia market growth.

Key companies in the hemophilia market are developing innovative drugs, such as ALTUVIIIO, to maintain a competitive edge. For instance, in February 2023, Sanofi S.A., a France-based pharmaceutical company, launched ALTUVIIIO for hemophilia, which was approved by the U.S. Food and Drug Administration (FDA). Administered once weekly, ALTUVIIIO is the first hemophilia A medication to provide consistent to near-normal factor activity levels (above 40%) for most of the week, significantly reducing bleeding compared to prior factor VIII prophylaxis.

In February 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company specializing in hemophilia treatments, acquired Nimbus Therapeutics LLC for $4 billion. This acquisition strengthens Takeda’s late-stage pipeline, expands its portfolio across multiple indications, and enhances its potential patient impact, supporting sustained mid- to long-term growth. Nimbus Therapeutics LLC is a U.S.-based pharmaceutical company focused on developing and manufacturing hemophilia drugs.

Major companies operating in the hemophilia market are Kedrion S.p.A., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Baxter International Inc., CSL Limited, Biogen Inc., Grifols S.A., Octapharma AG, BioMarin Pharmaceutical Inc., GC Pharma, Alnylam Pharmaceuticals Inc., Bio Products Laboratory Ltd., Sangamo Therapeutics Inc., UniQure, Intellia tx, ProMetic BioSciences Ltd., Dimension Therapeutics, Amarna therapeutics, HEMA Biologics LLC, Aptevo Therapeutics, Arcturus Therapeutics Inc., Ferring Lakemedel AB, Chiesi Farmaceutici S.p.A.

North America was the largest region in the hemophilia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemophilia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemophilia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the hemophilia market by increasing costs of imported clotting factor concentrates, recombinant biologics, infusion devices, diagnostic kits, and cold-chain logistics components. Treatment providers in North America and Europe are most affected due to reliance on imported biologic therapies, while Asia-Pacific faces higher costs in plasma-derived product manufacturing. These tariffs are increasing treatment costs and affecting reimbursement dynamics. However, they are also supporting regional biologics manufacturing, local plasma fractionation investments, and long-term supply chain resilience.

The hemophilia market research report is one of a series of new reports that provides hemophilia market statistics, including hemophilia industry global market size, regional shares, competitors with a hemophilia market share, detailed hemophilia market segments, market trends and opportunities, and any further data you may need to thrive in the hemophilia industry. This hemophilia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hemophilia is a rare genetic disorder that impairs the body’s ability to clot blood properly, typically becoming apparent when a person experiences injury and bleeding. Hemophilia treatment involves various medical interventions and strategies designed to manage and address the bleeding tendencies associated with the disorder.

The main types of hemophilia include hemophilia A, hemophilia B, hemophilia C, and others. Hemophilia A is a genetic disorder caused by a deficiency of clotting factor VIII (factor 8). Treatments include replacement therapy, hemostatic agents, desmopressin, gene therapy, and other approaches. These therapies are administered across a range of end-users, including hospitals, clinics, home care settings, and other healthcare facilities.

The hemophilia market consists of revenues earned by entities by providing physical therapy, hemophilia centers (HTCs) and prophylactic care. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemophilia market consists of sales of hemophilia drugs and medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.